a progressive brain disorder that impacts memory, thinking and behaviour. As The Express reports, the new drug has been shown ...

Lecanemab is the first treatment for Alzheimer’s disease licensed for use in Great Britain that shows some evidence of ...

A groundbreaking medication designed to delay the onset of Alzheimer's has received approval for use within the EU. The drug, ...

In today’s fast-paced world, maintaining optimal cognitive function is more important than ever. Whether you’re a student ...

In today’s fast-paced world, the need for cognitive enhancement has never been greater. Maintaining optimal brain function is essential for success as we navigate through our daily responsibilities, ...

The first drug targeting the root cause of Alzheimer’s disease has been approved by the European Medicines Agency. Despite ...

The U.S. Food and Drug Administration approved Kebilidi (eladocagene exuparvovec-tneq), an adeno-associated virus ...

Researchers have discovered that the NMDA receptor (NMDAR), known for its role in learning and memory, also stabilizes brain activity by setting baseline neural network activity.

A drug used to treat glaucoma holds promise in the fight against various forms of dementia, according to University of ...

A European regulatory committee now recommends approval of the Alzheimer’s treatment lecanemab a few months after rejecting ...

The U.S. Food and Drug Administration approved PTC Therapeutics, Inc.'s Kebilidi (eladocagene exuparvovec-tneq) gene therapy for the ...

The European Union's drugs regulator reversed its decision to block the Alzheimer's drug lecanemab, a treatment aimed at ...